Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news
Promising breath-test for cancer
(Flinders University) The global quest to use a person's breath analysis for rapid, inexpensive and accurate early-stage testing for cancer and other diseases has taken a leap forward. In a new paper in the British Journal of Cancer, Flinders University researchers have reported significant progress in developing a method to test exhaled breath profiles which accurately differentiate head and neck cancer from non-cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2020 Category: Biology Source Type: news
Black lives also matter in cancer care
(University of Colorado Anschutz Medical Campus) It is not biology, but access to health care that is causing Black Non-Hispanic patients with squamous cell cancer of the head and neck to have lower survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news
Decreasing treatment delays for head and neck cancer patients in South Carolina
(Medical University of South Carolina) Investigators from MUSC Hollings Cancer Center classify barriers to a recommended therapy for head and neck cancer that may mean the difference between life and death for these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news
US Health Department's Caputo has cancer, spokesperson says
A spokesperson says Trump health appointee Michael Caputo has metastatic head and neck cancer (Source: ABC News: Health)
Source: ABC News: Health - September 24, 2020 Category: Consumer Health News Tags: Health Source Type: news
A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges a...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news
Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges a...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news
NIDCR Science News - September 2020
Having trouble viewing this email? View it as a Web page.
A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH.
Shining a Light on Coronavirus Antibodies
Repurposed detection method gives glowing results
NIDCR • August 19, 2020
Turning Back the Clock on Gum Disease
Scientists reverse periodontitis in aged mice
NIDCR • July 20, 2020
Scientists Chew on a New Theory of Swallowing
Imaging in monkeys reveals ne...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news
NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Fall 2020 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities
NIH/HHS News
Funding Notices
Science Advances
Subscribe to NICDR News
Grantee News
NIDCR News
NIDCR Announces Availability of COVID-19 Research Funding
On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructure or i...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news
Blood marker may reduce cancer burden
(Flinders University) Researchers at Flinders University are expanding work on a promising blood test model to help predict or diagnose head and neck cancer, a difficult cancer to pick up early and treat.With cancer accounting for almost 10 million a year, the Global Burden of Disease report (2017) attributed more than 380,000 deaths to head and neck cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 1, 2020 Category: Biology Source Type: news
Cephalic Vein for Venous Anastomosis in the Head and Neck Cephalic Vein for Venous Anastomosis in the Head and Neck
In this article, the authors describe a technique which includes harvesting the cephalic vein for venous anastomosis in cases of head and neck cancer reconstruction.ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2020 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news
